Decoy Therapeutics (DCOY) Depreciation & Amortization (CF) (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Depreciation & Amortization (CF) of $5924.0 for Q1 2026, up 435.62% year-over-year from $1106.0 in Q1 2025, and up 54.55% quarter-over-quarter from $3833.0 in Q4 2025.
Decoy Therapeutics (DCOY) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $5924.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 435.62% year-over-year to $5924.0; the TTM figure through Mar 2026 stood at $11969.0 (up 170.61% YoY), while the FY2025 annual figure was $7151.0, up 61.64% from the prior year.
- Depreciation & Amortization (CF) rose to $5924.0 in Q1 2026 per DCOY's latest filing, from $3833.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $5924.0 in Q1 2026 and bottomed at -$1457.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $2013.4 across 5 years, with a median of $1107.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 130.38% — and 2026, when it soared 435.62%.
- Decoy Therapeutics' Depreciation & Amortization (CF) stood at $1669.0 in 2022, then plunged by 33.79% to $1105.0 in 2023, then grew by 0.09% to $1106.0 in 2024, then jumped by 246.56% to $3833.0 in 2025, then surged by 54.55% to $5924.0 in 2026.
- Business Quant data shows DCOY's Depreciation & Amortization (CF) at $5924.0 in Q1 2026, $3833.0 in Q4 2025, and $1106.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 13,632.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,632.00 |
| Jun 30, 2026 | 13,632.00 |
| Mar 31, 2026 | 5,924.00 |
| Mar 31, 2026 | 5,924.00 |
| Dec 31, 2025 | 3,833.00 |
| Dec 31, 2025 | 3,833.00 |
| Sep 30, 2025 | 1,106.00 |
| Sep 30, 2025 | 1,106.00 |
| Jun 30, 2025 | 1,106.00 |
| Jun 30, 2025 | 1,106.00 |
| Mar 31, 2025 | 1,106.00 |
| Mar 31, 2025 | 1,106.00 |
| Dec 31, 2024 | 1,106.00 |
| Dec 31, 2024 | 1,106.00 |
| Sep 30, 2024 | 1,105.00 |
| Sep 30, 2024 | 1,105.00 |
| Jun 30, 2024 | 1,106.00 |
| Jun 30, 2024 | 1,106.00 |
| Mar 31, 2024 | 1,107.00 |
| Mar 31, 2024 | 1,107.00 |